CN109232599A - 具有抗肿瘤活性的o-对三氟甲基苯甲酰基土甘草a及其制备方法和用途 - Google Patents
具有抗肿瘤活性的o-对三氟甲基苯甲酰基土甘草a及其制备方法和用途 Download PDFInfo
- Publication number
- CN109232599A CN109232599A CN201811168485.XA CN201811168485A CN109232599A CN 109232599 A CN109232599 A CN 109232599A CN 201811168485 A CN201811168485 A CN 201811168485A CN 109232599 A CN109232599 A CN 109232599A
- Authority
- CN
- China
- Prior art keywords
- radix glycyrrhizae
- trifluoromethylbenzoyl
- soil
- preparation
- soil radix
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000002689 soil Substances 0.000 title claims abstract description 39
- -1 trifluoromethylbenzoyl Chemical group 0.000 title claims abstract description 34
- 230000000259 anti-tumor effect Effects 0.000 title claims abstract description 16
- 238000002360 preparation method Methods 0.000 title claims abstract description 14
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims abstract description 24
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims abstract description 10
- 238000006243 chemical reaction Methods 0.000 claims abstract description 6
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims abstract description 5
- 239000002904 solvent Substances 0.000 claims abstract description 4
- 239000002253 acid Substances 0.000 claims abstract description 3
- 239000011230 binding agent Substances 0.000 claims abstract description 3
- 238000010992 reflux Methods 0.000 claims abstract description 3
- MXIUWSYTQJLIKE-UHFFFAOYSA-N 2-(trifluoromethyl)benzoyl chloride Chemical compound FC(F)(F)C1=CC=CC=C1C(Cl)=O MXIUWSYTQJLIKE-UHFFFAOYSA-N 0.000 claims description 9
- 239000002246 antineoplastic agent Substances 0.000 claims description 5
- 229940041181 antineoplastic drug Drugs 0.000 claims description 5
- 235000009508 confectionery Nutrition 0.000 claims description 5
- 238000010534 nucleophilic substitution reaction Methods 0.000 claims description 4
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 claims description 2
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 2
- 238000010438 heat treatment Methods 0.000 claims 1
- 238000002474 experimental method Methods 0.000 abstract description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 abstract description 2
- 230000001093 anti-cancer Effects 0.000 abstract description 2
- 229960000935 dehydrated alcohol Drugs 0.000 abstract description 2
- 238000001816 cooling Methods 0.000 abstract 1
- 238000000338 in vitro Methods 0.000 abstract 1
- 239000002994 raw material Substances 0.000 abstract 1
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 24
- 210000004027 cell Anatomy 0.000 description 16
- 241000252212 Danio rerio Species 0.000 description 14
- 239000000243 solution Substances 0.000 description 11
- 150000001875 compounds Chemical class 0.000 description 10
- 210000001161 mammalian embryo Anatomy 0.000 description 9
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 8
- 230000002159 abnormal effect Effects 0.000 description 7
- 239000003814 drug Substances 0.000 description 7
- 230000002401 inhibitory effect Effects 0.000 description 7
- 206010028980 Neoplasm Diseases 0.000 description 6
- 201000011510 cancer Diseases 0.000 description 6
- 229940079593 drug Drugs 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 239000012530 fluid Substances 0.000 description 5
- 231100000419 toxicity Toxicity 0.000 description 5
- 230000001988 toxicity Effects 0.000 description 5
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 230000008901 benefit Effects 0.000 description 3
- ZYGHJZDHTFUPRJ-UHFFFAOYSA-N coumarin Chemical compound C1=CC=C2OC(=O)C=CC2=C1 ZYGHJZDHTFUPRJ-UHFFFAOYSA-N 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 201000007270 liver cancer Diseases 0.000 description 3
- 208000014018 liver neoplasm Diseases 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 238000012545 processing Methods 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 2
- 238000005160 1H NMR spectroscopy Methods 0.000 description 2
- 208000024172 Cardiovascular disease Diseases 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- 238000005481 NMR spectroscopy Methods 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 230000013020 embryo development Effects 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- 239000001257 hydrogen Substances 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 238000011081 inoculation Methods 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 238000004321 preservation Methods 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- XVMSFILGAMDHEY-UHFFFAOYSA-N 6-(4-aminophenyl)sulfonylpyridin-3-amine Chemical compound C1=CC(N)=CC=C1S(=O)(=O)C1=CC=C(N)C=N1 XVMSFILGAMDHEY-UHFFFAOYSA-N 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 206010008342 Cervix carcinoma Diseases 0.000 description 1
- PQMOXTJVIYEOQL-UHFFFAOYSA-N Cumarin Natural products CC(C)=CCC1=C(O)C(C(=O)C(C)CC)=C(O)C2=C1OC(=O)C=C2CCC PQMOXTJVIYEOQL-UHFFFAOYSA-N 0.000 description 1
- 241000522195 Dalbergia Species 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 102000002322 Egg Proteins Human genes 0.000 description 1
- 108010000912 Egg Proteins Proteins 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 238000012404 In vitro experiment Methods 0.000 description 1
- 239000007836 KH2PO4 Substances 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- FSOGIJPGPZWNGO-UHFFFAOYSA-N Meomammein Natural products CCC(C)C(=O)C1=C(O)C(CC=C(C)C)=C(O)C2=C1OC(=O)C=C2CCC FSOGIJPGPZWNGO-UHFFFAOYSA-N 0.000 description 1
- FNVCLGWRMXTDSM-WOJBJXKFSA-N Samidin Chemical compound C1=CC(=O)OC2=C3[C@@H](OC(=O)C)[C@@H](OC(=O)C=C(C)C)C(C)(C)OC3=CC=C21 FNVCLGWRMXTDSM-WOJBJXKFSA-N 0.000 description 1
- 208000000875 Spinal Curvatures Diseases 0.000 description 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 230000010100 anticoagulation Effects 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 238000010009 beating Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 201000010881 cervical cancer Diseases 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 231100000045 chemical toxicity Toxicity 0.000 description 1
- 238000000546 chi-square test Methods 0.000 description 1
- OTAFHZMPRISVEM-UHFFFAOYSA-N chromone Chemical compound C1=CC=C2C(=O)C=COC2=C1 OTAFHZMPRISVEM-UHFFFAOYSA-N 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 229960000956 coumarin Drugs 0.000 description 1
- 235000001671 coumarin Nutrition 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 229910000397 disodium phosphate Inorganic materials 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 210000002257 embryonic structure Anatomy 0.000 description 1
- 230000001779 embryotoxic effect Effects 0.000 description 1
- 231100000238 embryotoxicity Toxicity 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000032050 esterification Effects 0.000 description 1
- 238000005886 esterification reaction Methods 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- 208000014829 head and neck neoplasm Diseases 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- 238000005286 illumination Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 231100000225 lethality Toxicity 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 208000026037 malignant tumor of neck Diseases 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 1
- 230000005311 nuclear magnetism Effects 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 210000004681 ovum Anatomy 0.000 description 1
- 238000009372 pisciculture Methods 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- GNSKLFRGEWLPPA-UHFFFAOYSA-M potassium dihydrogen phosphate Chemical compound [K+].OP(O)([O-])=O GNSKLFRGEWLPPA-UHFFFAOYSA-M 0.000 description 1
- XGPBRZDOJDLKOT-UHFFFAOYSA-N praeruptorin A Natural products C1=CC(=O)OC2=C1C=CC1=C2C(OC(C)=O)C(OC(=O)C(C)=CC)C(C)(C)O1 XGPBRZDOJDLKOT-UHFFFAOYSA-N 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000003672 processing method Methods 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- FNVCLGWRMXTDSM-UHFFFAOYSA-N samidin Natural products C1=CC(=O)OC2=C3C(OC(=O)C)C(OC(=O)C=C(C)C)C(C)(C)OC3=CC=C21 FNVCLGWRMXTDSM-UHFFFAOYSA-N 0.000 description 1
- 230000002000 scavenging effect Effects 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 231100000820 toxicity test Toxicity 0.000 description 1
- 238000012549 training Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
- C07D493/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Abstract
Description
Claims (6)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201811168485.XA CN109232599B (zh) | 2018-10-08 | 2018-10-08 | 具有抗肿瘤活性的o-对三氟甲基苯甲酰基土甘草a及其制备方法和用途 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201811168485.XA CN109232599B (zh) | 2018-10-08 | 2018-10-08 | 具有抗肿瘤活性的o-对三氟甲基苯甲酰基土甘草a及其制备方法和用途 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN109232599A true CN109232599A (zh) | 2019-01-18 |
CN109232599B CN109232599B (zh) | 2021-04-20 |
Family
ID=65055744
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201811168485.XA Expired - Fee Related CN109232599B (zh) | 2018-10-08 | 2018-10-08 | 具有抗肿瘤活性的o-对三氟甲基苯甲酰基土甘草a及其制备方法和用途 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN109232599B (zh) |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5216176A (en) * | 1989-01-23 | 1993-06-01 | Lehigh University | 7-alkoxycoumarins, dihydropsoralens, and benzodipyranones as photo-activated therapeutic agents and inhibitors of epidermal growth factor |
CN1425667A (zh) * | 2001-12-12 | 2003-06-25 | 方宏勋 | 一种具有抗肿瘤作用的新化合物、其制备方法及在制备治疗肿瘤药物中的应用 |
CN1860114A (zh) * | 2003-07-30 | 2006-11-08 | 埃斯特韦实验室有限公司 | 衍生自苯并噁嗪酮的磺酰胺化合物、其制备方法及作为药物的用途 |
WO2008102994A1 (en) * | 2007-02-22 | 2008-08-28 | Yong Jin Park | Composition comprising decursin derivative for treating and preventing atopic dermatitis |
CN104341430A (zh) * | 2014-09-30 | 2015-02-11 | 广西中医药大学 | 一种土甘草a及其提取方法和用途 |
CN104945408A (zh) * | 2015-04-30 | 2015-09-30 | 广西民族大学 | 香豆素类化合物及其制备方法和应用 |
-
2018
- 2018-10-08 CN CN201811168485.XA patent/CN109232599B/zh not_active Expired - Fee Related
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5216176A (en) * | 1989-01-23 | 1993-06-01 | Lehigh University | 7-alkoxycoumarins, dihydropsoralens, and benzodipyranones as photo-activated therapeutic agents and inhibitors of epidermal growth factor |
CN1425667A (zh) * | 2001-12-12 | 2003-06-25 | 方宏勋 | 一种具有抗肿瘤作用的新化合物、其制备方法及在制备治疗肿瘤药物中的应用 |
CN1860114A (zh) * | 2003-07-30 | 2006-11-08 | 埃斯特韦实验室有限公司 | 衍生自苯并噁嗪酮的磺酰胺化合物、其制备方法及作为药物的用途 |
WO2008102994A1 (en) * | 2007-02-22 | 2008-08-28 | Yong Jin Park | Composition comprising decursin derivative for treating and preventing atopic dermatitis |
CN104341430A (zh) * | 2014-09-30 | 2015-02-11 | 广西中医药大学 | 一种土甘草a及其提取方法和用途 |
CN104945408A (zh) * | 2015-04-30 | 2015-09-30 | 广西民族大学 | 香豆素类化合物及其制备方法和应用 |
Also Published As
Publication number | Publication date |
---|---|
CN109232599B (zh) | 2021-04-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102397269B (zh) | 查尔酮类化合物在制备抗炎药物中的应用 | |
CN105849111B (zh) | 吡喃并秋葵纤维异甲酚衍生物以及代谢综合征或炎症疾病治疗用药学组成物 | |
CN109438462A (zh) | 具有抗肿瘤活性的o-对硝基苯甲酰基土甘草a及其制备方法和用途 | |
PL234609B1 (pl) | 4'-O-β-D-4"-metoksyglukopiranozylo-6-metyloflawon i sposób wytwarzania 4'-O-β-D-4"-metoksyglukopiranozylo-6-metyloflawonu | |
CN104725372B (zh) | 四环吲哚生物碱衍生物及其制备和应用 | |
CN108484511A (zh) | 一种川芎嗪查尔酮类化合物及其制备方法和应用 | |
CN109232601A (zh) | 具有抗宫颈癌活性的土甘草a衍生物及其制备方法和用途 | |
CN109232599A (zh) | 具有抗肿瘤活性的o-对三氟甲基苯甲酰基土甘草a及其制备方法和用途 | |
CN109438461B (zh) | 具有抗白血病活性的土甘草a衍生物及其制备方法和用途 | |
CN114890882B (zh) | 柏木醇衍生物、其制备方法及其应用 | |
CN108285424B (zh) | 棉酚希夫碱衍生物及制备和在抗植物烟草花叶病毒病方面的应用 | |
CN109956868A (zh) | 一类苯基羧酸衍生物、其制备方法及其用途 | |
CN110028482A (zh) | 布雷菲德菌素a的4-位拼合美法仑类氮芥衍生物及其制备方法和用途 | |
CN109438463A (zh) | 具有抗肿瘤活性的o-(4-溴-2-氟苯甲酰基)土甘草a、及制备方法和用途 | |
CN105777718A (zh) | 潜在ezh2小分子抑制剂及其合成方法 | |
CN106946974B (zh) | 一类含吡唑杂环的熊果酰胺衍生物及其合成与应用 | |
CN108261414B (zh) | 一种治疗肺癌的药物组合物 | |
KR101629558B1 (ko) | 나프탈렌계 칼콘 및 그의 항암제로서의 용도 | |
CN104910074A (zh) | 一类含有羟肟酸基团的吡唑类衍生物及其制备方法及用途 | |
CN113045461B (zh) | 一种二苯乙烯型化合物及其合成方法与应用 | |
CN115010642B (zh) | β-榄香烯酰亚胺类衍生物及其应用 | |
CN115650972B (zh) | 一种槐定碱衍生物及其制备方法和应用 | |
CN110693864B (zh) | 一类三羰基化合物在制备抗人宫颈癌药物中的应用 | |
CN107056707B (zh) | 一种3,4,5-三甲氧基苯类化合物及其在制备抗氧化药物中的应用 | |
CN106632004B (zh) | 吡啶酮类衍生物及其制备方法与应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
CB03 | Change of inventor or designer information | ||
CB03 | Change of inventor or designer information |
Inventor after: Chen Rui Inventor after: Huo Lini Inventor after: Wei Jianhua Inventor after: Lu Rumei Inventor after: Li Dianpeng Inventor after: Wei Yanfei Inventor after: Li Peiyuan Inventor after: Zhong Haiyi Inventor before: Huo Lini Inventor before: Chen Rui Inventor before: Wei Jianhua Inventor before: Lu Rumei Inventor before: Li Dianpeng Inventor before: Wei Yanfei Inventor before: Li Peiyuan Inventor before: Zhong Haiyi |
|
CF01 | Termination of patent right due to non-payment of annual fee | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20210420 |